Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer

Small cell lung cancer (SCLC) is an aggressive cancer showing a very poor prognosis because of metastasis formation at an early stage and acquisition of chemoresistance. One key driver of chemoresistance is the transcription factor Forkhead box protein M1 (FOXM1) that regulates cell cycle proliferat...

Descripción completa

Detalles Bibliográficos
Autores principales: Taromi, Sanaz, Lewens, Florentine, Arsenic, Ruza, Sedding, Dagmar, Sänger, Jörg, Kunze, Almut, Möbs, Markus, Benecke, Joana, Freitag, Helma, Christen, Friederike, Kaemmerer, Daniel, Lupp, Amelie, Heilmann, Mareike, Lammert, Hedwig, Schneider, Claus-Peter, Richter, Karen, Hummel, Michael, Siegmund, Britta, Burger, Meike, Briest, Franziska, Grabowski, Patricia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722545/
https://www.ncbi.nlm.nih.gov/pubmed/29228593
http://dx.doi.org/10.18632/oncotarget.21221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722545/
https://www.ncbi.nlm.nih.gov/pubmed/29228593
http://dx.doi.org/10.18632/oncotarget.21221

Ejemplares similares